Gary D Kao
Medical Practice in Penn Wynne, PA
License number
New Jersey 25MA06828900
Issued Date
Oct 30, 1998
Expiration Date
Jun 30, 2011
Category
Medical Examiners
Type
Medical Doctor
Address
Address
Penn Wynne, PA
Professional information
Compounds For Treatment Of Malignant Tumors
US Patent:
8541476, Sep 24, 2013
Filed:
Sep 12, 2008
Appl. No.:
12/677478
Inventors:
Constantinos Koumenis - Philadelphia PA, US
Brian E. Lally - Miami FL, US
Steven Kridel - Clemmons NC, US
Gary D. Kao - Wynnewood PA, US
Adeboye Adejare - Mantua NJ, US
Brian E. Lally - Miami FL, US
Steven Kridel - Clemmons NC, US
Gary D. Kao - Wynnewood PA, US
Adeboye Adejare - Mantua NJ, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
Wake Forest University Health Sciences - Winston-Salem NC
University of the Sciences in Philadelphia - Philadelphia PA
Wake Forest University Health Sciences - Winston-Salem NC
University of the Sciences in Philadelphia - Philadelphia PA
International Classification:
A61K 31/10, C07C 315/00, C40B 30/06
US Classification:
514709
Abstract:
The present invention comprises compounds, compositions and methods of use for sensitizing cancer cells, tumors, neoplasms, and malignancies to the effects of ionizing radiation used in the treatment of cancer. The invention further comprises a method of identifying novel radiosensitizing compounds.
Cellular Targets For Treatment Of Retroviral Infection
US Patent:
2006002, Feb 2, 2006
Filed:
Mar 30, 2005
Appl. No.:
11/093692
Inventors:
Rene Daniel - Ambler PA, US
Anna Skalka - Princeton NJ, US
Gary Kao - Wynnewood PA, US
Giuseppi Nunnari - Cantania, IT
Roger Pomerantz - Chalfont PA, US
Anna Skalka - Princeton NJ, US
Gary Kao - Wynnewood PA, US
Giuseppi Nunnari - Cantania, IT
Roger Pomerantz - Chalfont PA, US
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435006000, 435007100
Abstract:
Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.
Cellular Targets For Treatment Of Retroviral Infection
US Patent:
2011008, Apr 14, 2011
Filed:
Jun 14, 2010
Appl. No.:
12/815125
Inventors:
Rene Daniel - Ambler PA, US
Anna Marie Skalka - Princeton NJ, US
Gary D. Kao - Wynnewood PA, US
Giuseppe Nunnari - Cantania, IT
Roger J. Pomerantz - Chalfont PA, US
Anna Marie Skalka - Princeton NJ, US
Gary D. Kao - Wynnewood PA, US
Giuseppe Nunnari - Cantania, IT
Roger J. Pomerantz - Chalfont PA, US
International Classification:
C12N 5/071
US Classification:
435366, 435325
Abstract:
Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.